Effectiveness of maintenance therapy of lithium vs other mood stabilizers in monotherapy and in combinations: a systematic review of evidence from observational studies

Bipolar Disorders

Volumn 20, Issue 5, 2018, Pages 419-431

  Kessing, Lars Vedel ^a,b   Bauer, Michael ^c   Nolen, Willem A ^d   Severus, Emanuel ^c   Goodwin, Guy M ^e   Geddes, John ^e  

^a Psychiatric Center Copenhagen   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

^c UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^d UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^e WARNEFORD HOSPITAL   (United Kingdom)

Author keywords

bipolar disorder; lithium; mania; mood stabilizer; non randomized trial; observational

Indexed keywords

ANTICONVULSIVE AGENT; ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; CARBAMAZEPINE; LAMOTRIGINE; LITHIUM; MOOD STABILIZER; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; VALPROIC ACID;

ADD ON THERAPY; BIPOLAR DISORDER; BIPOLAR I DISORDER; BIPOLAR II DISORDER; COMBINATION DRUG THERAPY; DRUG EFFICACY; DRUG SUBSTITUTION; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; HOSPITAL READMISSION; HUMAN; MAINTENANCE THERAPY; MONOTHERAPY; PRIORITY JOURNAL; RECURRENT DISEASE; RELAPSE; REVIEW; SYSTEMATIC REVIEW;

EID: 85042025987     PISSN: 13985647     EISSN: 13995618     Source Type: Journal    
DOI: 10.1111/bdi.12623     Document Type: Review

References (60)

1. Kessing LV, Hansen MG, Andersen PK. Course of illness in depressive and bipolar disorders. Naturalistic study, 1994-1999. Br J Psychiatry. 2004;185:372-377.
2. Tohen M, Hennen J, Zarate CM Jr, et al. Two-year syndromal and functional recovery in 219 cases of first-episode major affective disorder with psychotic features. Am J Psychiatry. 2000;157:220-228.
3. Bourne C, Aydemir O, Balanza-Martinez V, et al. Neuropsychological testing of cognitive impairment in euthymic bipolar disorder: an individual patient data meta-analysis. Acta Psychiatr Scand. 2013;128:149-162.
4. Wells KB. Treatment research at the crossroads: the scientific interface of clinical trials and effectiveness research. Am J Psychiatry. 1999;156:5-10.
5. Miura T, Noma H, Furukawa TA, et al. Comparative efficacy and tolerability of pharmacological treatments in the maintenance treatment of bipolar disorder: a systematic review and network meta-analysis. Lancet Psychiatry. 2014;1:351-359.
6. Severus E, Taylor MJ, Sauer C, et al. Lithium for prevention of mood episodes in bipolar disorders: systematic review and meta-analysis. Int J Bipolar Disord. 2014;2:15.
7. Lindstrom L, Lindstrom E, Nilsson M, Hoistad M. Maintenance therapy with second generation antipsychotics for bipolar disorder - A systematic review and meta-analysis. J Affect Disord. 2017;213:138-150.
8. Grunze H, Vieta E, Goodwin GM, et al. The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of bipolar disorders: update 2012 on the long-term treatment of bipolar disorder. World J Biol Psychiatry. 2013;14:154-219.
9. Bowden CL, Calabrese JR, McElroy SL, et al. A randomized, placebo-controlled 12-month trial of divalproex and lithium in treatment of outpatients with bipolar I disorder. Divalproex Maintenance Study Group. Arch Gen Psychiatry. 2000;57:481-489.
10. Geddes JR, Goodwin GM, Rendell J, et al. Lithium plus valproate combination therapy versus monotherapy for relapse prevention in bipolar I disorder (BALANCE): a randomised open-label trial. Lancet. 2010;375:385-395.
11. Bowden CL, Calabrese JR, Sachs G, et al. A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently manic or hypomanic patients with bipolar I disorder. Arch Gen Psychiatry. 2003;60:392-400.
12. Calabrese JR, Bowden CL, Sachs G, et al. A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently depressed patients with bipolar I disorder. J Clin Psychiatry. 2003;64:1013-1024.
13. Licht RW, Nielsen JN, Gram LF, Vestergaard P, Bendz H. Lamotrigine versus lithium as maintenance treatment in bipolar I disorder: an open, randomized effectiveness study mimicking clinical practice. The 6th trial of the Danish University Antidepressant Group (DUAG-6). Bipolar Disord. 2010;12:483-493.
14. Tohen M, Chengappa KN, Suppes T, et al. Relapse prevention in bipolar I disorder: 18-month comparison of olanzapine plus mood stabiliser v. mood stabiliser alone. Br J Psychiatry. 2004;184:337-345.
15. Tohen M, Greil W, Calabrese JR, et al. Olanzapine versus lithium in the maintenance treatment of bipolar disorder: a 12-month, randomized, double-blind, controlled clinical trial. Am J Psychiatry. 2005;162:1281-1290.
16. Weisler RH, Nolen WA, Neijber A, Hellqvist A, Paulsson B. Continuation of quetiapine versus switching to placebo or lithium for maintenance treatment of bipolar I disorder (Trial 144: a randomized controlled study). J Clin Psychiatry. 2011;72:1452-1464.
17. Bowden CL, Vieta E, Ice KS, Schwartz JH, Wang PP, Versavel M. Ziprasidone plus a mood stabilizer in subjects with bipolar I disorder: a 6-month, randomized, placebo-controlled, double-blind trial. J Clin Psychiatry. 2010;71:130-137.
18. Yatham LN, Kennedy SH, Parikh SV, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2013. Bipolar Disord. 2013;15:1-44.
19. NICE. Bipolar disorder: the assessment and management of bipolar disorder in adults, children and young people in primary and secondary care. NICE Clinical Guideline 185, 2015.
20. Goodwin GM, Haddad PM, Ferrier IN, et al. Evidence-based guidelines for treating bipolar disorder: revised third edition recommendations from the British Association for Psychopharmacology. J Psychopharmacol. 2016;30:495-553.
21. Helsedirektoratet AphorO. Nasjonal fagleg retningslinje for utgreiing og behandling av bipolare lidingar. IS-1925, 2012.
22. Rådet for Anvendelse af Dyr Sygehusmedicin (RADS). Baggrundsnotat for medicinsk behandling af bipolar lidelse. 2015. http://www.regioner.dk/medicinsite/rads/behandlingsvejledninger/~/media/2DCA28127D004C4294342F7279E63252.ashx. Accessed November 18, 2015.
23. Kupka R, Grossens P, Van Bendegem M, et al. Multidisciplinaire richtlijn bipolaire stoornissen; derde, herziene versie. De Tijdstroom, Utrecht, 2015. https://www.nvvp.net/stream/richtlijn-bipolaire-stoornissen-2015. Accessed February 2, 2018.
24. Baldessarini RJ. Treatment research in bipolar disorder: issues and recommendations. CNS Drugs. 2002;16:721-729.
25. Kessing LV. Treatment options in bipolar disorder: lessons from population-based registers with focus on lithium. Curr Treat Options Psychiatry. 2015;2:218-228.
26. Hayes JF, Osborn D. Observational BALANCE. Br J Psychiatry. 2011;199:341-342.
27. Calabrese JR, Kemp DE. Bipolar drug development: are we getting closer to the real world? Am J Psychiatry. 2008;165:1234-1236.
28. Licht RW. Limitations in randomised controlled trials evaluating drug effects in mania. Eur Arch Psychiatry Clin Neurosci. 2001;251(Suppl.2):II66-II71.
29. Black N. Why we need observational studies to evaluate the effectiveness of health care. BMJ. 1996;312:1215-1218.
30. Munk-Jorgensen P, Kastrup M, Mortensen PB. The Danish psychiatric register as a tool in epidemiology. Acta Psychiatr Scand Suppl. 1993;370:27-32.
31. Munk-Jorgensen P, Mortensen PB. The Danish psychiatric central register. Dan Med Bull. 1997;44:82-84.
32. Mors O, Perto GP, Mortensen PB. The Danish psychiatric central research register. Scand J Public Health. 2011;39:54-57.
33. Allebeck P. The use of population based registers in psychiatric research. Acta Psychiatr Scand. 2009;120:386-391.
34. Coppen A, Abou-Saleh MT. Plasma folate and affective morbidity during long-term lithium therapy. Br J Psychiatry. 1982;141:87-89.
35. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6:e1000097.
36. Wingard L, Boden R, Brandt L, et al. Reducing the rehospitalization risk after a manic episode: a population based cohort study of lithium, valproate, olanzapine, quetiapine and aripiprazole in monotherapy and combinations. J Affect Disord. 2017;217:16-23.
37. Hayes JF, Marston L, Walters K, Geddes JR, King M, Osborn DP. Lithium vs. valproate vs. olanzapine vs. quetiapine as maintenance monotherapy for bipolar disorder: a population-based UK cohort study using electronic health records. World Psychiatry. 2016;15:53-58.
38. Kessing LV, Hellmund G, Andersen PK. An observational nationwide register based cohort study on lamotrigine versus lithium in bipolar disorder. J Psychopharmacol. 2012;26:644-652.
39. Kessing LV, Hellmund G, Geddes JR, Goodwin GM, Andersen PK. Valproate v. lithium in the treatment of bipolar disorder in clinical practice: observational nationwide register-based cohort study. Br J Psychiatry. 2011;199:57-63.
40. Baldessarini RJ, Leahy L, Arcona S, Gause D, Zhang W, Hennen J. Patterns of psychotropic drug prescription for U.S. patients with diagnoses of bipolar disorders. Psychiatr Serv. 2007;58:85-91.
41. Simhandl C, Konig B, Amann BL. A prospective 4-year naturalistic follow-up of treatment and outcome of 300 bipolar I and II patients. J Clin Psychiatry. 2014;75:254-262.
42. Kraemer S, Minarzyk A, Eppendorfer S, et al. Comparably high retention and low relapse rates in different subpopulations of bipolar patients in a German non-interventional study. BMC Psychiatry. 2013;13:193.
43. Altamura AC, Mundo E, Dell'Osso B, Tacchini G, Buoli M, Calabrese JR. Quetiapine and classical mood stabilizers in the long-term treatment of Bipolar Disorder: a 4-year follow-up naturalistic study. J Affect Disord. 2008;110:135-141.
44. Garnham J, Munro A, Slaney C, et al. Prophylactic treatment response in bipolar disorder: results of a naturalistic observation study. J Affect Disord. 2007;104:185-190.
45. Hochman E, Krivoy A, Schaffer A, Weizman A, Valevski A. Antipsychotic adjunctive therapy to mood stabilizers and 1-year rehospitalization rates in bipolar disorder: a cohort study. Bipolar Disord. 2016;18:684-691.
46. Patel NC, Crismon ML, Pondrom M. Rehospitalization rates of patients with bipolar disorder discharged on a mood stabilizer versus a mood stabilizer plus an atypical or typical antipsychotic. J Behav Health Serv Res. 2005;32:438-445.
47. Joas E, Karanti A, Song J, Goodwin GM, Lichtenstein P, Landen M. Pharmacological treatment and risk of psychiatric hospital admission in bipolar disorder. Br J Psychiatry. 2017;210:197-202.
48. Reed C, Novick D, Gonzalez-Pinto A, Bertsch J, Haro JM. Observational study designs for bipolar disorder - what can they tell us about treatment in acute mania? Prog Neuropsychopharmacol Biol Psychiatry. 2009;33:715-721.
49. Zimmerman M, Mattia JI, Posternak MA. Are subjects in pharmacological treatment trials of depression representative of patients in routine clinical practice? Am J Psychiatry. 2002;159:469-473.
50. Keitner GI, Posternak MA, Ryan CE. How many subjects with major depressive disorder meet eligibility requirements of an antidepressant efficacy trial? J Clin Psychiatry. 2003;64:1091-1093.
51. Partonen T, Sihvo S, Lonnqvist JK. Patients excluded from an antidepressant efficacy trial. J Clin Psychiatry. 1996;57:572-575.
52. Reinares M, Vieta E, Colom F, et al. Impact of a psychoeducational family intervention on caregivers of stabilized bipolar patients. Psychother Psychosom. 2004;73:312-319.
53. Henry C, Andreassen OA, Barbato A, et al. European Network of Bipolar Research Expert Centre (ENBREC): a network to foster research and promote innovative care. Int J Bipolar Disord. 2013;1:2.
54. Berk M, Daglas R, Dandash O, et al. Quetiapine v. lithium in the maintenance phase following a first episode of mania: randomised controlled trial. Br J Psychiatry. 2017;210:413-421.
55. Daglas R, Cotton SM, Allott K, et al. A single-blind, randomised controlled trial on the effects of lithium and quetiapine monotherapy on the trajectory of cognitive functioning in first episode mania: A 12-month follow-up study. Eur Psychiatry. 2016;31:20-28.
56. Nolen WA. Long-term treatment of mood disorders: follow-up of acute treatment phase studies versus continuation and maintenance phase studies, and enriched versus non-enriched designs. In: Tohen M, Bowden C, Nierenberg A, Geddes J, eds. Clinical Trial Design Challenges in Mood Disorders. Cambridge MA: Academic Press; 2015.
57. Smith KA, Cipriani A. Lithium and suicide in mood disorders: updated meta-review of the scientific literature. Bipolar Disord. 2017;19:575-586.
58. Kessing LV, Forman JL, Andersen PK. Does lithium protect against dementia? Bipolar Disord. 2010;12:87-94.
59. Kessing LV, Sondergard L, Forman JL, Andersen PK. Lithium treatment and risk of dementia. Arch Gen Psychiatry. 2008;65:1331-1335.
60. Kessing LV, Vradi E, Andersen PK. Nationwide and population-based prescription patterns in bipolar disorder. Bipolar Disord. 2016;18:174-182.